IgA Nephropathy
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
On Market (1)
Approved therapies currently available
Competitive Landscape
18 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 19 trials with date data
Clinical Trials (20)
Total enrollment: 1,770 patients across 20 trials
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Atacicept in Subjects With IgA Nephropathy
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
Study of CM313 in Subject With IgA Nephropathy
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
Study of BHV-1400 in IgA Nephropathy
Study of ARO-CFB in Adult Healthy Volunteers
Managed Access Programs for EXV811, Atrasentan
Related Jobs in Nephrology
Director, Bioanalytical / Biomarkers
Associate Director Advocacy
Senior Director Patient Advocacy
Senior Manager Patient Advocacy
Director, Statistical Programming
Associate Director Clinical Data Management
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.